The serine/threonine kinase Raf-1 acts downstream of Ras in the MAPK pathway leading to ERK activation in response to mitogens. Raf-1 has oncogenic potential, but is normally controlled by a complex interplay of inhibitory and activating mechanisms. Although Raf-1 is phosphorylated in unstimulated cells, mitogens cause its membrane recruitment by Ras and subsequent phosphorylation on additional sites. Some of these events modulate Raf-1 kinase activity while others determine interactions with other proteins. These changes regulate the ability of Raf-1 to phosphorylate its downstream targets MEK1 and MEK2. Rho family small G proteins act synergistically with Raf-1 to stimulate the ERK pathway by a cross-cascade mechanism that enhances MEK phosphorylation by Raf-1. Here we show that both Raf-1 and MEK1 are phosphorylated by PAK1 and that mutations at PAK1 phosphorylation sites in either protein prevent cross-cascade activation. In contrast, MEK1 activation by constitutively-active Raf-1 is refractory to mutations at PAK1 phosphorylation sites. Phosphorylation of MEK1 on serine 298 does not appear to regulate the interaction between Raf-1 and MEK1, but rather the ability of Raf-1 to phosphorylate MEK1 with which it is complexed in vivo. Our ®ndings indicate that PAK1 primes MEK1 for activation by Raf-1 and imply another level of regulation in the ERK cascade.
Introduction
Cell proliferation is regulated by growth factors and mitogens, which act through cell surface receptors to orchestrate changes in gene expression and numerous other cellular events. Pivotal for the transmission of intracellular signals is the protein kinase Raf-1 (Kolch, 2000; Morrison and Cutler, 1997) . It consists of a Cterminal serine/threonine kinase domain and an Nterminal regulatory domain in which two conserved regions, CR1 and CR2, have been de®ned. Activation of Raf-1 requires its recruitment to the cell membrane by GTP-bound Ras, through interactions between the eector domain of Ras and the Ras-Binding domain (RBD) present in CR1 of Raf-1.
Once at the cell membrane, Raf-1 activation is in¯uenced by several events. A cysteine-rich domain (CRD), also present in CR1, is necessary for ecient Raf-1 activation and may serve to alleviate allosteric inhibition by interacting with Ras (Winkler et al., 1998) . Raf-1 is phosphorylated in unstimulated cells on at least three serine residues (43, 259, 621) , one of which (259) lies in CR2 (Morrison et al., 1993) . Protein Kinase A (PKA)-mediated suppression of Raf-1 results in hyperphosphorylation of these sites (Dhillon et al., 2002; HaÈ fner et al., 1994; Mischak et al., 1996; Wu et al., 1993) , while Protein phosphatase 2A, which associates with Raf-1, acts as a positive regulator by dephosphorylating them (Abraham et al., 2000) . Serines 259 and 621 serve as recognition sites for the ubiquitous 14-3-3 scaolding proteins, implicated in both Raf-1 activation and inhibition (Kolch, 2000) .
Raf-1 activation also correlates with phosphorylation on numerous serine residues and, in some circumstances, on tyrosine residues (Marais et al., 1995; Mason et al., 1999) , events in which several kinases have been implicated (Kolch, 2000 and references therein) . In particular, serine 338 has been identi®ed as a target for p21-Activated Kinases (PAKs) (Chaudhary et al., 2000; King et al., 1998) . None the less, all these regulatory events can be subverted, as demonstrated by the v-raf oncogene, in which the Raf-1 N-terminal domain is replaced by viral gag sequences that serve to locate the active kinase domain at the cell membrane.
Raf-1 lies at the head of the Mitogen-Activated Protein Kinase (MAPK) cascade. Once activated, Raf-1 phosphorylates MEKs, which in turn phosphorylate ERKs (Robinson and Cobb, 1997) . Active ERKs dimerise (Khokhlatchev et al., 1998) and phosphorylate a range of cytoplasmic targets, including structural proteins and p90 RSK kinases (Robinson and Cobb, 1997) . In addition, ERKs translocate to the nucleus (Chen et al., 1992) where they activate numerous transcription factors by direct phosphorylation, the paradigm being Ternary Complex Factors (TCFs) such as Elk-1 and Sapla (Wasylyk et al., 1998) . Upon phosphorylation by ERKs, TCFs are recruited by Serum Response Factor (SRF) to the promoters of immediate early genes, thus mediating their activation by growth factors. The persistent stimulation of these nuclear events underlies the ability of several oncogenes to deregulate cell proliferation . Other signalling pathways are able to modulate the activation of ERK by the MAPK cascade. As indicated above, in response to elevated cAMP levels PKA can downregulate ERK activity, in part by direct phosphorylation of Raf-1 (Kolch, 2000) . Conversely, Rho family small G proteins, which normally activate the cJun N-terminal Kinase/Stress-Activated Protein Kinase (JNK/SAPK) pathway, potentiate growth factor stimulation of the ERK pathway and downstream events including TCF-dependent gene expression by acting in synergy with Raf-1 to activate MEKs. This crosscascade activation was shown to be mediated by PAK1 and to involve the enhanced association of Raf-1 and MEK1 (Frost et al., 1997) . Phosphorylation of MEK1 on two residues in a short proline-rich insert was found to be a key event in the process.
Here we dissect the underlying mechanism of crosscascade activation in more detail. We have found that mutations in Raf-1 previously shown to impair its regulation by Phosphatidylinositol-3OH-Kinase (PI3K) and PAKs (Chaudhary et al., 2000; King et al., 1998; Sun et al., 2000) block cross-cascade activation. However, a PI3K-independent Raf-1 containing phosphomimetic residues is equally inactive. Similarly, an alanine mutation at serine 298 within the proline rich region of MEK1, which is phosphorylated by PAK1, also blocks cross-cascade activation. PAK1 phosphorylation of MEK1 does not appear to in¯uence the interaction between Raf-1 and MEK1, but rather the ability of Raf-1 to phosphorylate MEK1 in vivo, indicating that PAK1 phosphorylation primes MEK1 for activation by Raf-1.
Results
Rho family small G proteins are able to act synergistically with Raf-1 to stimulate the ERK pathway and downstream gene expression by a crosscascade pathway (Frost et al., 1997) . The mechanism was shown to involve PAK1 insofar as a constitutivelyactive PAK1 could substitute for activated Rac1 and cdc42, while a dominant inhibitory version of PAK1 suppressed cross-cascade activation. It has also been reported that in response to PI3K signalling Raf-1 can be up-regulated by phosphorylation of serine 338 and argued that PAKs target this residue in Raf-1 (Chaudhary et al., 2000; Sun et al., 2000) .
Raf-1 phosphorylation by PAK1 is insufficient for cross-cascade activation
In order to assess the role of PAK1 in cross-cascade activation further, we ®rst examined phosphorylation of Raf-1 on serine 338 under circumstances in which cross-cascade activation is observed. As shown in Figure 1a , co-expression of Raf-1 with an active mutant of PAK1 led to strong phosphorylation of Raf-1 on serine 338, consistent with the notion that PAK1 phosphorylates Raf-1 at this site in vivo.
We next compared the ability of two Raf-1 mutants, 338/9AC and 338/9DE, to support the cross-cascade synergy with Rac1QL or PAK165. We used 338/9 double mutants because in the absence of serine 338, compensatory phosphorylation of serine 339 has been observed (King et al., 1998) . The 338/9AC mutant of Raf-1, which cannot be activated by Ras (Diaz et al., 1997) or TPA (our unpublished data), was unable to promote MEK1 phosphorylation with either PAK165 or Rac1QL (Figure 1b, c) . Furthermore, the 338/9DE mutant, which contains phosphomimetic substitutions Figure 1 Raf-1 mutations at serines 338/9 block cross-cascade activation by Rac1 and PAK1. (a) HEK293 cells were transfected with vectors for Raf-1 alone or Raf-1 and myc-PAK165. After serum-starvation for 24 h, cells were harvested and Raf-1 immunoprecipitates were collected with a mouse monoclonal antibody against Raf-1 and probed with the antibodies indicated. The panel shows non-adjacent lanes from the same immunoblot. (b) HEK293 cells were transfected with expression vectors for HA ± MEK1, myc-PAK165 and Raf-1 or mutants thereof, as indicated, and harvested after serum-starvation for 24 h. Immunoprecipitations were carried out with a rat monoclonal antibody against the HA epitope and immunoblots were probed with the antibodies shown to the left of each panel. Lanes 1 ± 6 and 7 ± 8 are non-adjacent lanes from the same blot. (c) HEK293 cells were transfected with expression vectors for HA ± MEK1, Rac1QL and Raf-1 or mutants thereof, as indicated, and harvested after serum-starvation for 24 h. Immunoprecipitations were carried out as in (b) and probed with the antibodies shown to the left of each panel and has been shown to relieve partially the requirement for PAK phosphorylation (Chaudhary et al., 2000; Diaz et al., 1997) , was also inactive in this assay ( Figure 1b , lane 8; Figure 1c , lane 5). Consistent with this observation, the 338/9DE mutant of Raf-1 failed to compensate for an inactive PAK1 (Figure 2a ; lane 6). In contrast, a constitutively active Raf-1 mutant, S259D, induced MEK1 phosphorylation either alone or in the presence of a dominant-inhibitory PAK1 (Figure 2a , lanes 1 and 4) and MEK1 phosphorylation by Raf259D was not further enhanced by co-expression of PAK165 (data not shown). To show that the 338/9 mutations did not compromise Raf-1 function altogether, we introduced both 338/9 mutations into Raf259D and tested the ability of the double mutants to stimulate MEK1 phosphorylation. As anticipated, both 259D+338/9AA and 259D+338/9DE double mutants induced MEK1 phosphorylation almost as well as 259D alone ( Figure  2b , lanes 4 and 5), demonstrating that substitutions at serine 338/9 of Raf-1 do not prevent Raf-1 activation per se. Thus phosphorylation of serine 338 by PAK1 may be important for cross-cascade synergy (Figure 1 ), but it is not absolutely necessary for MEK1 activation.
Cross-cascade activation induces MEK phosphorylation on threonine 292 and serine 298
Two residues in MEK1 (threonine 292 and serine 298) are thought to be important for its synergistic activation by Raf-1 and Rho family proteins and PAK1 has been shown to phosphorylate MEK1 on serine 298 in vitro (Frost et al., 1997) . In order to monitor phosphorylation at these residues, we generated phospho-speci®c antibodies against each site in MEK1. To test the speci®city of the antibodies, we prepared GST ± MEK1 phosphorylated with immunoprecipitated PAK165 or recombinant, active ERK2 or both. As shown in Figure  3a , substitution of serine 298 with alanine prevented phosphorylation of GST ± MEK1 by PAK1 (lanes 3 and 7, lower panels), con®rming that serine 298 is the only PAK1 phosphorylation site in MEK1. Conversely, substitution of threonine 292 with alanine reduced phosphorylation by ERK2 by 75% (lanes 4 and 8, upper panels), suggesting that this is the primary, but not the only ERK2 site in MEK1. This is consistent with a previous report showing that ERK2 is able to phosphorylate MEK1 on threonines 292 and 386 (Mansour et al., 1994) .
Recombinant GST ± MEK1, phosphorylated in vitro as described above, was used to characterise the phospho-speci®c antibodies. As anticipated, the antiphospho threonine 292 antibody only recognised GST ± MEK1 after phosphorylation by PAK1 ( Figure 3b , upper panel, lanes 3 and 4). Similarly, the anti-phospho serine 298 antibody reacted strongly with GST ± MEK1 after phosphorylation by ERK2 but not by PAK1 ( Figure 3b , lower panel, lanes 2 and 4), although this antibody also reacted detectably with unphosphorylated GST ± MEK1. The phospho-speci®c antibodies also recognised MEK1 immunoprecipitated from cell lysates, whereas the corresponding alanine substitution mutants were detected only weakly (MEK298A: Figure 3c ) or not at all (MEK292A: see Figure 4c ). These analyses thus con®rm the speci®city of the two antibodies.
We used the threonine 292 and serine 298 phosphospeci®c antibodies to monitor the phosphorylation of MEK1 during cross-cascade activation. The comparison of MEK1 and MEK298A in Figure 3c suggests that MEK1 may be phosphorylated weakly on serine 298 in unstimulated cells. However, we observed that PAK165, when co-expressed with MEK1 in HEK293 cells, caused an increase in MEK1 phosphorylation on serine 298 ( Figure 4a , lanes 3 and 4), notably under circumstances in which PAK1-dependent phosphorylation of Raf-1 on serine 338 also took place ( Figure 1a , lane 2). Thus it seems likely that PAK1 phosphorylates MEK1 on serine 298 in vivo. PAK1 also consistently stimulated phosphorylation of threonine 292 ( Figure 4b , upper panel, lane 3) while co-expression of Raf-1 had no further eect (lane 4). Overall, the expression of Raf-1 alone had a variable eect on phosphorylation of MEK1 on threonine 292, ranging from weak phosphorylation to a level equalling that induced by PAK165 (Figure 4b , lane 2 and results not shown). However, as PAK1 is unable to phosphorylate threonine 292 in vitro, it appears unlikely that this residue in MEK1 is phosphorylated by PAK1 in vivo. Taken together, our analyses show that MEK1 is phosphorylated in vivo on serine 298 but also on threonine 292 during cross-cascade activation. Phosphorylation of both sites correlates with PAK1 activity, but threonine 292 is unlikely to be a direct target of PAK1. Having established the pattern of MEK1 phosphorylation on threonine 292 and serine 298, we assessed the roles of these two sites in MEK1 during cross-cascade activation mediated by PAK1. Although threonine 292 is phosphorylated in response to PAK165 expression (Figure 4b ), its substitution with alanine has no eect on the phosphorylation of MEK1 at serines 218/222, as shown in Figure 4c , lane 3 (lower panels). The levels of MEK1 phosphorylation at serines 218/222 shown in Figure 4b and c are directly comparable because the results are taken from the same experiment. However, the substitution of serine 298 almost completely abolished MEK1 phosphorylation on serines 218/222 (Figure 4c , lane 5). The double mutant, T292A/S298A, ablated cross-cascade activation of MEK1 altogether (Figure 4c, lane 7) . These results indicate that serine 298 in MEK1 is essential for cross-cascade activation of the ERK pathway by Rho family proteins and in Figure 3 Phospho-speci®c antibodies for residues threonine 292 and serine 298 in MEK1. (a) Wild type GST ± MEK1 (top left panel), GST ± MEK292A (top right), GST ± MEK298A (bottom left) and GST ± MEK292/298A (bottom right), were incubated alone (lanes 2 and 6), with immunoprecipitated myc-PAK165 (lanes 3 and 7), active ERK2 (lanes 4 and 8) or immunoprecipitated myc-PAK165 and ERK2 (lanes 5 and 9) in the presence of 32 P-labeled g-ATP. Lane 1 shows GST ± MEK1 incubated with a control immunoprecipitation from mock-transfected cells. Reactions were separated by SDS ± PAGE and the dried gels were visualized using a phosphorimager. Numbers in the boxes above the gels represent moles of phosphate incorporated per mole of MEK1, expressed as percentages. (b) GST ± MEK1 plus ATP were incubated alone, with immunoprecipitated myc-PAK165, active ERK2 or both, as indicated. Reactions were separated by SDS ± PAGE and analysed by immunoblotting with the antibodies shown to the left of each panel. (c) HEK293 cells were transfected with expression vectors for wt HA ± MEK1 or the S298A mutant, as indicated, and harvested after serum-starvation for 24 h. Immunoprecipitations were carried out with a rat monoclonal antibody against the HA epitope and immunoblots were probed with the antibodies shown to the left of each panel conjunction with the preceding data, that it is likely to be a direct phosphorylation site in MEK1 for PAK1.
To examine the catalytic activity of the MEK298A mutant, we performed immune-complex kinase assays with kinase-dead ERK1 as substrate. As Raf-1 is known to form complexes with MEK1, we ®rst compared the ability of MEK1 and MEK298A to coimmunoprecipitate Raf-1 from cell lysates. Raf-1 was indeed found in complex with MEK1, but no dierence in the amount of Raf-1 complexed with the two proteins could be detected (Figure 5a, compare lanes 2  and 4) . Given the presence of Raf-1 in MEK immunoprecipitates, we included the speci®c Raf-1 inhibitor ZM 336372 (Hall-Jackson et al., 1999) in the assays to prevent subsequent MEK1 phosphorylation and activation by Raf-1 in vitro. Under these circumstances, the kinase activity of MEK1 was stimulated 6.4-fold, whereas MEK 298A showed a much weaker (2.1-fold) response (Figure 5b , compare lane 5 in upper and lower panels). This result is consistent with the relative phosphorylation of MEK1 and MEK 298A on serines 218/222 (Figure 4c ). However, in the absence of ZM 336372, no dierence between MEK1 and MEK298A activity was observed (lane 6), indicating that co-immunoprecipitated Raf-1 was able to phosphorylate and activate MEK1 and MEK 298A to similar levels in vitro. This is borne out by the increased incorporation of 32 P into MEK1 and MEK298A in the absence of inhibitor (upper bands in both upper panels), which mirrors in each case the incorporation into kinase-dead ERK1. Taken together, these results indicate that while Raf-1 associates equally well with MEK1 and MEK 298A and is capable of phosphorylating and activating both in vitro, it does not activate MEK 298A in vivo.
Mutations at the PAK1 phosphorylation site in Raf-1 (338/9AC) blocked cross-cascade activation of the ERK pathway, but could be complemented in cis by an activating Raf-1 mutant (Figure 2b ). It was therefore of interest to see if the same mutation could also compensate in trans for the MEK1 298A mutation. In contrast to its deleterious eect on the cross-cascade stimulation of MEK1 phosphorylation, mutation of serine 298 had no detrimental eect on MEK1 phosphorylation in response to Raf 259D (Figure 6a) . Furthermore, activation of MEK1 by constitutivelyactive V 12 Ras was also unaected by the S298A or T292A mutations in MEK1 (Figure 6b ). These data indicate that point mutations in both Raf-1 and MEK1 can speci®cally prevent cross-cascade activation of the ERK pathway by PAK1 or Rho family proteins, but not the activation of MEK1 by constitutively-active versions of Raf-1 or Ras.
Discussion
We have examined here the mechanism by which Rho family G proteins act in synergy with Raf-1 to stimulate the ERK pathway. Consistent with our earlier implication of PAK1 in these events, we observe that cross-cascade activation correlates with phosphorylation of Raf-1 on serine 338 and that mutation of serine 338 in Raf-1 abrogates synergy with PAK1. In addition, we observe PAK1-dependent phosphorylation of MEK1 on serine 298 and that substitution of serine 298 in MEK1 also blocks synergy. Although this mutation reduces the degree of MEK1 phosphorylation and activation by Raf-1 in vivo, it appears to have no detrimental eect on the interaction between Raf-1 and MEK1, nor does it reduce MEK1 phosphorylation by Raf-1 in vitro.
PAK1 phosphorylation of Raf-1 on serine 338
The complex role of serine phosphorylation in Raf-1 function is exempli®ed by serines 338/9, which lie immediately N-terminal to the kinase domain. Serine Figure 5 In¯uence of MEK1 mutants on cross-cascade activation by PAK1. (a) HEK293 cells were transfected with expression vectors for Raf-1 and HA ± MEK1 or HA ± MEK298A, as indicated, and harvested after serum-starvation for 24 h. MEK1 immunoprecipitates were collected with a rat monoclonal antibody against the HA epitope. (b) HEK293 cells were transfected with expression vectors for Raf-1, myc-PAK165, HA ± MEK1 or HA ± MEK298A, as indicated, and harvested after serumstarvation for 24 h. Kinase activity of immunoprecipitated MEK1 towards kinase-dead ERK1(K71R) was measured in the presence (lanes 1 ± 5) or absence (lane 6) of 50 mM ZM 336372. Dried SDS ± PAGE gels were visualized and quantitated by phosphorimaging (upper panels) the numbers above the panels show intensity of the kinase-dead ERK1 band relative to wt MEK1 in lane 3. Samples of the lysates taken prior to immunoprecipitation were immunoblotted with the indicated antibody (lower panels). Lanes 5 and 6 of upper panels represent pooled duplicate samples (lysate shown in lane 5, lower panels), equal portions of which were assayed in the presence or absence of ZM 336372, as indicated 338 is phosphorylated by PAKs in vitro and removal of this site reduces Raf-1 activation by several upstream stimuli, including V 12 Ras, PI3K and phorbol esters (Chaudhary et al., 2000; Diaz et al., 1997; King et al., 1998; Sun et al., 2000 and our unpublished data) . Conversely, substitution of serine 338 with the phosphomimetic residue aspartate partially relieves the requirement for PAK during Raf-1 activation by Ras or P13K, and the additional substitution of serine 339 with glutamate enhances the eect (Chaudhary et al., 2000; Diaz et al., 1997) . However, these mutations alone do not activate Raf-1 kinase, implying that phosphorylation of serine 338 may contribute to, but does not determine Raf-1 activation. It has also been suggested that S338 phosphorylation occurs independently of PI3K-dependent PAK activity and hypothesised that other kinases may target this residue (Chiloeches et al., 2001) . Both serines are conserved in B-Raf but the counterpart of serine 338 appears to be constitutively phosphorylated (Mason et al., 1999) . In contrast, activation of B-Raf requires phosphorylation of threonine 598 and serine 601 and phosphomimetic substitutions at these sites render the kinase constitutively active (Zhang and Guan, 2000) . The role of the corresponding residues in Raf-1 (threonine 491 and serine 494) is presently unknown.
In the case of cross-cascade activation, although we observe PAK1-dependent phosphorylation of Raf-1 on serine 338 and a loss of synergy due to alanine mutations at serines 338/9, the introduction of phosphomimetic residues does not relieve the requirement for Rac1 or PAK1 even partially. Importantly, the combination of the 338/9 mutations in cis with the activating 259D mutation demonstrated that the mutations at serines 338/9 do not simply compromise Raf-1 kinase function. Thus phosphorylation of Raf-1, although important, is unlikely to be the sole function of PAK1 in the cross-cascade activation mechanism.
PAK1 phosphorylation of MEK1 on serine 298
We originally reported that cross-cascade activation involves the phosphorylation of MEK1 on serine 298 by PAK1 (Frost et al., 1997) . In this study our antiserine 298 phospho-speci®c antibody con®rms that the expression of active PAK1 stimulates the phosphorylation of MEK1 on serine 298 under circumstances that induce phosphorylation of Raf-1 on serine 338, a further indication that PAK1 phosphorylates MEK1 on serine 298 in vivo. However, phosphorylation of this residue does not appear to be sucient to trigger the cross-cascade mechanism since it occurs under conditions when MEK1 is not activated. Although the antiserine 298 phospho-speci®c MEK1 antibody clearly distinguishes MEK1 phosphorylated on serine 298, it appears to have a relatively low anity for its epitope. For this reason it is dicult to gauge the proportion of MEK1 that becomes phosphorylated on serine 298 during cross-cascade activation.
More conclusive evidence that serine 298 in MEK1 is important for synergy is the demonstration that its mutation to alanine almost completely abolishes crosscascade activation of MEK1. This was re¯ected in the degree of MEK1 phosphorylation on serines 218/222 and in immune-complex kinase assays in which the activity of MEK1 298A, measured in the presence of a Raf-1 inhibitor to prevent MEK1 activation in vitro by co-immunoprecipitated Raf-1, was reduced by 60%. Again, several lines of evidence indicate that the mutation does not impair the intrinsic activity of MEK1. Active Raf 259D and V12-Ras both stimulate phosphorylation of MEK1 and MEK 298A with equal eciency, while kinase assays performed in the absence of ZM 336372 demonstrated that MEK1 and MEK 298A are equally active following in vitro phosphorylation by co-immunoprecipitated Raf-1.
We also observed phosphorylation of threonine 292 in MEK1. Threonine 292 is one of two residues implicated in negative regulation of MEK1 (Rossomando et al., 1994) . It has also been demonstrated that threonine 292 is a target for feedback phosphorylation by ERK2, although phosphorylation at this site and at threonine 386 was found to have no eect on the catalytic activity of MEK1 in vitro (Mansour et al., 1994) . Although phosphorylation of threonine 292 was consistently observed in conjunction with PAK165 expression, it could not be phosphorylated in vitro by PAK1 and its mutation had no adverse eect on crosscascade activation of MEK1. Moreover, phosphorylation of threonine 292 occurred under circumstances in which MEK1 remained inactive, suggesting that feedback phosphorylation was not the cause. Thus threonine 292 remains paradoxical insofar as its phosphorylation follows PAK1 activity but it is unlikely to be a PAK1 substrate and has no apparent role in cross-cascade activation of the ERK pathway. Ras, as indicated, and harvested after serum-starvation for 24 h. Immunoprecipitations were carried out with a rat monoclonal antibody against the HA epitope and immunoblots were probed with the antibodies shown to the left of each panel Role of MEK1 phosphorylation on serine 298 in cross-cascade activation Serine 298 and threonine 292 lie within a proline-rich insert found between subdomains IX and X of MEK1 and MEK2 that is absent from other MAPK kinases. Deletion of the proline-rich insert from MEK1 was reported to attenuate its activation in response to mitogen stimulation and block its ability to associate with Raf-1 and, indirectly, Ras (Catling et al., 1995; Jelinek et al., 1994) . Consistent with these ®ndings, mutation of serine 298 and threonine 292 was shown to impair the association of MEK1 and Raf-1 (Frost et al., 1997) . Subsequently, however, deletion of the proline-rich insert was found to have no eect on MEK1 association with or activation by Raf-1, but to impair the activation of downstream ERKs (Dang et al., 1998) . Here we also ®nd that an alanine substitution at serine 298 has no eect on the interaction between Raf-1 and MEK1, consistent with the premise that the proline-rich insert is not the MEKRaf-1 interaction domain. However, we do ®nd that mutation of serine 298 blocks cross-cascade-mediated phosphorylation of MEK1 on serines 218/222 in vivo and the consequent ability of MEK1 to phosphorylate ERK1, without compromising MEK1 phosphorylation and activation by co-immunoprecipitated Raf-1 in vitro. Thus our results are consistent with the idea that PAK1 phosphorylation of Raf-1 and MEK1 plays a modulatory role in MEK1 activation during crosscascade activation.
In the absence of compelling data to indicate that phosphorylation of serine 338 upregulates the kinase activity of Raf-1, or that phosphorylation of the proline-rich insert is indispensable for MEK1 activation by Raf-1, the cross-cascade mechanism must involve an additional component to integrate these two events. Several other proteins are known to interact with Raf-1. For example, 14-3-3 proteins interact with Raf-1 through two phospho-serine residues. In one model describing Raf-1 regulation, 14-3-3 is proposed to constrain Raf-1 in an inactive conformation. However, removal of 14-3-3 by competition has been shown to prevent Raf-1 activity entirely (Tzivion et al., 1998) . Thus 14-3-3 proteins have been suggested to play both a negative and a positive role, possibly by recruiting regulatory proteins into a complex with Raf-1 (Kolch, 2000) . Candidates include the kinase Breakpoint Cluster Region (BCR), Kinase Suppressor of Ras (KSR) and Raf-1 itself (Kolch, 2000 and references therein). Preliminary results also indicate that PAK1 may be present in a complex with Raf-1 and MEK1 (our unpublished data). However, whether these associations are direct or indirect and if PAK1 has other potential target(s) during crosscascade activation of the ERK pathway remains to be determined. It is also noteworthy that the deletion of the proline-rich insert in MEK1 has been reported to prevent its interaction with MP1, a small scaolding protein that confers on MEK1 a speci®city for ERK1 (Schaeer et al., 1998) . We are currently assessing the role of such potential components of the Raf-1-MEK1 complex in cross-cascade activation of the ERK pathway.
Materials and methods

Cell culture
HEK293 cells were grown in DMEM supplemented with 10% FCS, 100 U/ml Penicillin and 0.1 mg/ml Streptomycin. Cells were transfected by DNA-calcium phosphate coprecipitation as described (Frost et al., 1997) .
Plasmids
The expression plasmids pCMV-Raf-1, pCMV-Raf259D, pCMV-RafK375W (kinase-dead), pMCL-MKK1wt, pMCL-MKK292A, pMCL-MKK298A, pMCL-MKK292/298AA, pCDNA3-Rac1QL, pCMV-PAK1(165-544), pCMV-PAK165(K298A) and pRc/CMV-V 12 Ras have been described (Frost et al., 1997) .
The plasmid pCMV-Raf338/9AC was created by inserting a Raf-1-internal SalI fragment with the corresponding mutation, which was generated via two-step PCR mutagenesis, into pCMV-Raf-1.
The plasmid pCMV-Raf338/9DE was generated by introduction of the mutation into pCMV-Raf-1 with the QuikChange Kit (Stratagene). Similarly, the plasmids pCMV-Raf259D+338/9AA and pCMV-Raf259D+338/9DE were generated by introducing the corresponding 338/9 mutations into pCMV-Raf259D.
The plasmid pGEX ± MEK1 has been described elsewhere (Zheng and Guan, 1993) . The bacterial expression vectors pGEX-MEK292A, pGEX-MEK298A and pGEX-MEK292/ 298AA were generated by sub-cloning EcoRI fragments from the corresponding pMCL-MKK1 derivatives into pGEX ± MEK1.
All sequences generated by PCR were veri®ed by DNA sequencing. All mutations introduced by the QuikChange Method were veri®ed by DNA sequencing. Further details are available on request.
Antibodies
Polyclonal antisera speci®c for MEK1 phospho-T292 and MEK1 phospho-S298 were generated by immunising rabbits with the following KLH-coupled phosphopeptides: CTPPRPRT P PGRPL and CPGRPLS P SYGMDS. Reactivity to unphosphorylated MEK1 was removed from the antisera by peptide anity chromatography. A rat monoclonal anti-HA antibody was purchased from Roche and the mouse monoclonal anti-myc antibody (clone 9E10) was from Santa Cruz. Rabbit polyclonal antibodies speci®c for total MEK1/2 and MEK phospho-S218/222 were purchased from New England Biolabs and the c-Raf-1 mouse monoclonal antibody was from Transduction Laboratories. The phospho-S338-speci®c anti-Raf-1 rat monoclonal antibody was from Upstate Biotech.
Immunoprecipitations and Immunoblotting (Westerns)
Cells were lysed in buer B (20 mM Tris-HCl pH 7.8, 50 mM NaF, 40 mM Na 4 P 2 O 7 , 5 mM MgCl 2 10 mM Na 3 VO 4 , 1% Triton X-100, 0.1% SDS and 5 mM Benzamidine, supplemented with 1 mg/ml pepstatin, leupeptin and aprotinin and 0.2 mM PMSF). Of the total lysate 2 ± 8% was used for SDS ± PAGE analysis followed by immunoblotting. Proteins were immunoprecipitated from the remainder with 2 mg of anti-HA antibody, 0.5 mg of anti-Raf-1 antibody or 0.2 mg of 9E10 antibody and 25 ml of protein G sepharose (Pharmacia) by tumbling at 48C for 2 h. Immunoprecipitates were washed three times with buer B, eluted in SDS loading buer and analysed by SDS ± PAGE followed by immunoblotting. For immunecomplex kinase assays alternative lysis and wash buers were used. In the case of HA-MEK proteins, the lysis and wash buer was 20 mM Tris-HCl pH 7.4, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 20 mM b-glycerophosphate, 20 mM NaF and 20 mM sodium pyrophosphate, supplemented with 1 mg/ml pepstatin, leupeptin and aprotinin and 0.2 mM PMSF. In the case of myc-PAK165, the lysis buer was 50 mM b-glycerophosphate pH 7.2, 100 mM Na 3 VO 4 , 2 mM MgCl 2 , 1 mM EGTA, 0.5% Triton X-100 and 1 mM DTT supplemented with 1 mg/ml pepstatin, leupeptin and aprotinin and 0.2 mM PMSF. Washes were performed with 20 mM Tris-HCl pH 7.4, 150 mM NaCl and 1 mM DTT.
In vitro kinase reactions
Recombinant GST ± MEK1 proteins were prepared as described (Zheng and Guan, 1993) . Brie¯y, the proteins were expressed in E. coli strain TG-1 and 1 l cultures in 26YT medium were induced with 10 mM IPTG when the OD 600 reached 0.6. The cells were harvested after 16 h at 258C, lysed by passage through a French press and the recombinant protein puri®ed using glutathione agarose resin (Sigma). Proteins were eluted from the resin with 10 mM glutathione, then dialysed into buer lacking glutathione and stored at 7808C. His-tagged, active ERK2 and kinase-dead ERK1(K71R) were prepared as detailed elsewhere (Khokhlatchev et al., 1997) .
In vitro phosphorylation of GST ± MEK1 proteins by recombinant, active ERK2 and immunoprecipitated myc-PAK165 was carried out in 2 mM Tris-HCl pH 8.0, 10 mM MgCl 2 , 1 mM DTT, 100 mM ATP, for 1 h at 308C with the addition of 2 c.p.m. of [ 32 P]g-ATP per fmole of ATP where indicated. Active ERK2 and the GST ± MEK1 derivatives were present at 400 nM. Incorporation of phosphate into the GST ± MEK1 derivatives was measured by scintillation counting of excised bands. The kinase activity of immunoprecipitated HA ± MEKs was assayed in 20 mM Tris-HCl pH 7.4, 20 mM NaCl, 10 mM MgCl 2 , 1 mM DTT, 50 mM ATP with 4 c.p.m. of [ 32 P]g-ATP per fmole of ATP, at 308C for 30 min in the presence of 320 nM kinase-dead ERK1. Reactions were stopped by the addition of 36SDS loading buer and analysed by SDS ± PAGE followed by phosphorimaging of the dried gels.
